Phlebotomy

Regular Off Off

The Pathology Phlebotomy Team based in the Brunel building at Southmead Hospital Bristol managed by Anna Dacey Phlebotomy Manager (mobile 07725605670). She is responsible for the team and the services they provide.

A phlebotomy service is available to all wards (except Maternity and ITU):

  • Monday to Friday, 7:00am and 2.00pm
  • Saturday and Sunday a reduced service is provided between 7.30am and 11.30am
  • Bank Holiday a reduced service is provided between 7.30am and 11.30am

Please note that there is no arrangement in place for urgent “on demand” phlebotomy.

We carry out all phlebotomy requests including cross matching and group and holds.

All ICE requests must be on the system by 6.30am on the day required, or they will automatically go onto the next days round

The phlebotomists cannot accept paper requests (except transfusion requests where paper is required), all requests must be put on ICE.

On weekends and bank holidays there are limited numbers of Phlebotomists working and we would ask that you would try to keep the number of requests down to a minimum.

Dynamic function tests and samples requiring collection at a specific time should be collected by the medical staff. 

Patients can be bled for certain specialised or labile tests (by prior agreement) at agreed times.

Information for patients is available on the following area of our website Having a blood sample taken | North Bristol NHS Trust (nbt.nhs.uk).

Training

The phlebotomy team has qualified trainers within the Brunel building at Southmead Hospital who regularly provide training in venepuncture to clinical staff, following their attendance at the venepuncture study day.

For North Bristol NHS Trust staff there is no charge for this service. Trainees will be accommodated as soon as possible, but this is dependent on staffing levels and a trainer availability.

Please contact the phlebotomy manager if you wish to undertake training in venepuncture with the phlebotomy team.

Contact Phlebotomy

Any queries regarding the phlebotomy service should be directed to:

Anna Dacey
Phlebotomy Manager
Telephone: 07725605670 or 0117 4143204

Lorraine Mallinson
Lead phlebotomist
Telephone: 0117 4143203

Test Information

Sample vials for testing

Includes details of sample types, volumes, special precautions, turnaround times & reference ranges.

Phlebotomy

Colorectal Current Research

Regular Off Off

Colorectal Current Research

The Colorectal Research team at North Bristol NHS Trust offer patients and people at risk of developing Colon cancer excellent patient-centred care and the opportunity to participate in research.

Delivering complex interventional and observational studies, the team is comprised of  a multidisciplinary clinical team, supported by our research nurses and a Research Administrator. 

Please speak to the person treating you to see if there is a research study that may be able to help you.

Current Studies:

EXTEND

Bacteria live in the intestine to help digest food. If the intestine is damaged by an operation, injury or a disease such as cancer, bacteria can leak into the space surrounding the intestine (called the abdominal cavity) and cause a serious “intra-abdominal infection.” The usual treatment for this is a course of antibiotics (usually for 7 – 18days) and sometimes surgery too. But unfortunately, these infections are complicated and the treatment doesn’t always work. In 50% of patients the infection will return, or they will develop a new one further down the line. This is called “treatment failure” and requires another course of antibiotics, and possibly more surgery.

However, current research suggests that a longer course of antibiotics may benefit these patients by preventing treatment failure and further hospital admissions. So, the EXTEND trial will be comparing an extended course of antibiotics (28 days) against the normal duration of antibiotics (7 – 18 days). Each participant will be allocated by chance into one of these two groups and will be closely monitored for the next 6 months to see if the extended course of antibiotics offers a benefit to patients by reducing the rate of treatment failure.

Principal Investigator: Anne Pullybank

Planned End Date: 30/06/2025

Local Ref (R&D no): 5187

MELMART-II

The study aims to further medical knowledge and may improve future treatment of melanoma. The study will investigate how much skin should be removed from around the melanoma during wider excision surgery. Currently, doctors do not know how much skin to remove from around a melanoma to reduce the chances of it coming back. Guidelines in different countries vary in their recommendations on this. This study will investigate if reducing the excision margin to 1cm is as good at reducing the risk of melanoma returning as a 2cm excision margin.

 

Principal Investigator: Mr Ewan Wilson

Planned End Date: 01/07/2029

Recruitment to end 01/07/2025

Local Ref (R&D no): 4755

CVLP

The NHS Cancer Vaccine Launch Pad (CVLP) is looking to find people who may be able to take part in research trials for personalised vaccines to treat cancer. By supporting these trials, NHS England (NHSE) aims to speed up the development of personalised treatments for cancer patients. 

We are offering patients having their cancer removed or biopsied the opportunity to have their cancer DNA analysed for changes that could be targeted for personalised treatment. The CVLP is looking for people who may be suitable for cancer vaccine research trials. Vaccines are usually used to stop people from getting a disease, such as polio or measles. Researchers are now looking at using vaccines to stop cancer coming back after it has already been treated. Cancer vaccines stimulate the body’s immune system to recognise and attack cancer cells.  

Cancer vaccines are designed using genetic (DNA) changes found in a person’s cancer. They are individually made for each person. Cancer vaccines are being tested in research trials to understand how well they work. 

Project Details

PI: Ann Lyons

Planned End date: 31/12/2030

Local Ref: 5497

GRACE

Hospital acquired thrombosis describes blood clots that form in the legs and lungs after someone is treated in hospital. A clot in the leg can cause swelling, pain and other problems. If a clot in the leg breaks off and travels to the lungs, it may be life threatening. Having surgery increases the risk of developing blood clots. Blood clots in the legs and/or lungs are collectively known as venous thromboembolism (VTE).  

Doctors have known about the risks of patients developing blood clots after operations for many years and use two main ways to prevent this: 

  • Thinning the blood with injections / tablets, and 

  • Wearing elastic stockings to help stop blood sitting in the leg veins where it can clot. 

All participants who undergo surgery that puts them at higher risk of developing VTE require the blood thinners to be taken post discharge from hospital. Currently, some hospitals provide elastic stockings in addition to blood thinners but other hospital do not. There are no good quality research studies to show if the addition of elastic stockings reduces the risk of VTEs in patients taking blood thinners after discharge from hospital. This study is being done to find out if this is true.  

Project Details

PI: Anne Pullyblank

Planned End date: 31/07/2027

Local Ref: 5522

Gondomar

Perianal fistulising Crohn’s disease affects around one third of patients with Crohn’s disease during their course.  It is one of the most debilitating complications in Crohn’s disease.  Treatment methods are still evolving and approaches involving a combination of medical treatments and a number of surgical techniques are proposed.  However, the efficacy of these approaches to achieve clinically relevant outcomes is uncertain.  The majority of the recommendations are based upon expert opinion and there is relatively little scientific evidence to guide Crohn’s Disease perianal fistula (CD-pAF) management.

Our research is vital to understand the causes and consequences of problems in Crohn’s disease and improve the lives of those affected.  We aim to convert our research findings into clear improvements in health and services for people with Crohn’s disease with perianal fistula.  You could help by taking part in research that is relevant to you.  This might be to do with symptoms that you have now, or that you’ve had in the past, or even symptoms that you have never had (for comparison to other people who have).

Project Details

PI: Caroline Burt

Planned End date: 31/12/2030

Local Ref: 5495

Take Part in Research

Patient & Doctor viewing an x-ray

Become one of the thousands of people taking part in research every day within the NHS.

About Research & Development

NBT Researcher

Find out more about our research and how we're working to improve patient care.

Contact Research

Research & Development
North Bristol NHS Trust
Level 3, Learning & Research building
Southmead Hospital
Westbury-on-Trym
Bristol, BS10 5NB

Telephone: 0117 4149330
Email: research@nbt.nhs.uk

R&I Colorectal.jpg

Smoking in Pregnancy

Regular Off Off

Smoking during pregnancy is linked to numerous health complications for both mother and baby.

There are thousands of harmful chemicals in cigarettes that enter the bloodstream and are passed to the developing baby.

Stopping smoking by 15-weeks reduces your chance of having a small baby or delivering prematurely.

Stopping smoking at any point in pregnancy immediately benefits you and your and baby. 

Benefits of stopping smoking

Quitting smoking at any time during pregnancy is the best thing you can do to improve your baby’s health, growth and development. It is also the single most important thing you can do to improve your long-term health. Some of the benefits include:

  • Fewer complications during and after pregnancy
  • Reduced risk of miscarriage
  • Reduced risk of stillbirth
  • Reduced risk of premature birth – this can cause additional breathing, feeding and health complications
  • Reduced risk of sudden infant death (also known as cot death)
  • The baby is more likely to be born a healthy weight – this means it is better-equipped to cope with labour and is less prone to infections in the first few months

What support can we offer?

We know that stopping smoking is difficult, so we offer dedicated support for at least 12 weeks.

Our friendly Treating Tobacco Dependency (TTD) advisors can help to identify strategies and tools to manage nicotine cravings. There are various nicotine replacement therapies (NRT) which are safe to take while pregnant – the hospital can supply these for free.

The combination of counselling and NRT is 3 times more likely to result in a successful quit attempt.

Carbon Monoxide (CO)

  • Carbon monoxide is an odourless, colourless, poisonous gas that can have a devastating effect on pregnancy. When it is breathed in, it enters the bloodstream and passes to the baby through the placenta.
  • High levels of CO in the body during pregnancy prevent the baby from receiving the oxygen it needs to develop. This can cause miscarriage, stillbirth and premature birth. It also increases the risk of the child developing certain complications later in life.
  • The most common cause of high CO levels is cigarettes – this can be through smoking or breathing in second-hand smoke from someone else at home.
  • Other reasons for a high CO reading can include incorrectly installed or faulty cookers or boilers, faulty car exhausts, blocked chimneys or high levels of pollution. Barbeques and wood-burning stoves can also raise CO levels.
  • We check carbon monoxide levels at every appointment using a CO monitor. This helps us to provide the right advice and support.
  • We can help identify the cause of high CO levels and offer support to reduce the resulting risks.

Get in touch

Our Treating Tobacco Dependency advisors are happy to talk, even if you have not yet decided whether you would like to stop smoking. Please get in touch to find out more.

Email: TTDMaternity@NBT.nhs.uk

Text ‘Quit’ to 07407 817 470

Better Health

Check out more information on the Better Health website.

Useful resources

NHS Inform: Calculate My Savings

NHS Stop Smoking Website

Tommy’s - 7 Common Myths about Smoking

Tommy’s - 10 Great Reasons to Quit Smoking

App

NHS Quit Smoking App

A 28 day programme that puts practical support, encouragement, and tailored clinical advice in the palm of your hand. Available from the App Store or Google Play.

How to contact us

Brunel building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

07407 817 470

If you or the individual you are caring for need support reading this information please ask a member of staff for advice.

If you’re an overseas visitor, you may need to pay for your treatment or you could face fraud or bribery
charges, so please contact the overseas office:

Research Annual Report

Regular Off Off

Our highlights from 2022-23

We have:

  • Updated and refreshed our Research Strategy for the period 2022-2027
  • Exceeded previous achievements in research recruitment and research grant activity
  • Launched a new funding stream aimed at supporting early career non-medics
  • Initiated our patient engagement surveys.

Achieving all this was only possible through the engagement and collaboration of everyone within the research infrastructure, the Trust, regional partners, and our stakeholders.

The NBT Research Strategy forms the basis upon which both the department’s objectives are based, and our longer-term achievements are measured. 

We have identified our commitment to equality, diversity and inclusivity (EDI) and to the environment as cross-cutting themes or ‘Founding Principles’ which will be incorporated into all our aims.

See the full Research Annual Report

 

View Our Research

Doctor conducting research at NBT

Explore the ground-breaking research currently taking place at North Bristol NHS Trust.

About Research & Development

NBT Researcher

Find out more about our research and how we're working to improve patient care.

Contact Research

Research & Development
North Bristol NHS Trust
Level 3, Learning & Research building
Southmead Hospital
Westbury-on-Trym
Bristol, BS10 5NB

Telephone: 0117 4149330
Email: research@nbt.nhs.uk

Information Following Bariatric Surgery

Regular Off Off
Icon of a speech/thought bubble and question mark on the inside

Introduction

This information aims to increase your knowledge before and after your bariatric surgery. If there is anything you are unsure about, please ask.

Discharge from hospital

You are usually discharged by 10am the next day following your operation (except for gastric band patients who are discharged the same day). The doctor and specialist nurse will see you before discharge to ensure that you are medically fit to go home.

When you leave hospital

Complications should not happen very often, but it is important that you know what to look out for. During the first two weeks after surgery, if you are worried about any of the following, please phone the telephone numbers at the bottom of the page. If you cannot contact anyone you will need to contact your GP, NHS 111 or return to Southmead Hospital.

Abdominal pain

It is not unusual to have abdominal discomfort after having bariatric surgery. Worsening severe pain that lasts for several hours may indicate a leakage of fluid from the areas where the bowel and stomach has been joined together. This is a serious complication, which fortunately happens rarely. Should this occur, it may be accompanied by a fever.

If you experience worsening severe pain that lasts for several hours, you should contact the bariatric team immediately or come straight to Southmead Hospital A & E department.

Vomiting

Occasionally after surgery you can experience some nausea which is not unusual. You will be sent home with anti-sickness medication.

If you have persistent nausea and vomiting the bariatric team should be contacted immediately.

Wounds

There are normally 5-6 laparoscopic wound sites (the areas on your body where the laparoscope was used) that will have dissolvable stitches and glue over the top. You can continue to shower as usual but avoid baths until wounds are fully healed.

It is not unusual for your wounds to be slightly red and tender during the first 1-2 weeks.

You may also notice some bruising, but please let us know or contact GP if your wound:

  • Becomes more red, swollen, or painful.
  • Starts to discharge fluid/pus.
  • Your wound edges separate.

This may indicate an infection, please contact your GP or Practice Nurse.

Bowels

In the initial stages following surgery its quite common to have constipation or diarrhoea, due to eating less. If you have no bowel action for 3 days or more, ask your GP to prescribe you a laxative (Sugar Free Liquid Sodium Docusate), but avoid Fybogel or Movicol.

DVT (Deep Vein Thrombosis)

If you are having a Gastric Bypass, Sleeve or Band insertion, you will be going home self-administering Enoxaparin and wearing TED stockings for 2 weeks to prevent DVT.

However, a friend or family member can administer the Enoxaparin if preferred.

Enoxaparin contains product derived from pigs. If you have any ethical objections to the use of animal products, please discuss this with the team before using Enoxaparin.

Work

Many people can return to work within 4-6 weeks following their surgery, but your GP can extend this if required and a sick note will be given upon discharge if required.

Driving

It is advised that you do not drive until you are confident that you can drive safely. In general, this will be 2-4 weeks after surgery. It is important that any pain has resolved sufficiently to enable you to perform an emergency stop, check your blindspot and drive safely. You should contact your insurance company to check their terms.

Hobbies and activities

In general, it is advised that you take up your hobbies and activities as soon as possible again after surgery. It enables you to maintain your activity and will benefit your recovery.

We would not advise restricting your hobbies unless they cause significant pain or involve heavy lifting within the first 6 weeks after surgery.

We would also advise not to go swimming until the wounds have completely healed.

Sexual activities

Feeling tired and weak after an operation naturally affects your sex drive. As you gradually start to feel well again and your energy levels return to normal, so should your sex drive. Sexual intercourse can be resumed as soon as you feel comfortable, about 2-4 weeks after surgery.

We would advise you not to get pregnant for 18 months to 2 years after the operation, to protect yourself and the baby from potential malnutrition.

Medications

Your medications would have been discussed before your operation with the pharmacist and a plan created. You will be given painkillers and other medication to take home, including Lansoprazole which helps prevent acid reflux.

All medications need to be crushed or in liquid form (apart from the multivitamins/Calcium which are chewable).

Supplements

You need to take vitamins and minerals for life after your bariatric surgery.

If you have had a gastric bypass or sleeve gastrectomy you will also need vitamin B12 injections every 3 months.

  • Iron: Liquid Iron (Ferrous fumarate sugar free syrup 140mg/5ml), once daily at lunchtime. To improve absorption, please do not take it the same time as the calcium. Once you are back onto solid foods (normally by 4-6 weeks after surgery) you can switch to a tablet form of iron – please speak to your GP about this.
  • Calcium and Vitamin D: Adcal D3 which is one tablet to be chewed twice a day (morning and evening).
  • A-Z Multivitamin and Mineral: You will need to buy chewable A-Z multivitamins and take one dose two times a day. Once you are back onto solid foods (normally by 4-6 weeks after surgery) you should switch to a tablet A-Z multivitamin with minerals as these are more complete than the chewable ones. Suitable ones are listed in your main/large bariatric leaflet.
  • Vitamin B12 Injections: You will need to arrange this at your GP practice. You will require a 1mg, intramuscular injection 3 months after your operation, then every 3 months for the rest of your life.

All medication can be taken in tablet form 4-6 weeks after the operation.

Contact details

Bariatric Co-ordinators:

Bariatric Clinical Nurse Specialist: 0117 414 7557

If you or the individual you are caring for need support reading this information please ask a member of staff for advice.

If you’re an overseas visitor, you may need to pay for your treatment or you could face fraud or bribery charges, so please contact the overseas office:

Discharge from day surgery

Regular Off Off
Icon of a person standing outside the Brunel building with a suitcase

Discharge home

You will be given verbal information about wound care and pain relief and there is written information further down this page.

Day surgery staff will inform your escort when you are ready to go home. It is important that they are available to collect you and stay with you. We expect that you will go home the same day. However, if there are complications such as severe pain or sickness you may have to stay in hospital overnight. If you do have any problems when you arrive home, contact your district nurse or your own GP or NHS 111 Service.

We advise for 24 hours you should not:

  • Drive your car or any other vehicle.
  • Cook or operate machinery.
  • Drink alcohol or take sleeping tablets.
  • Do not make important decisions or sign legal documents for 24 hours.
  • Take sole charge of children.

Wound care

  • Keep your wound clean and dry until your stitches have dissolved/are removed.
  • If you have had a local anaesthetic take your own pain medication as necessary.
  • If you experience prolonged bleeding, severe pain or increased amount of swelling contact your GP or the NHS 111 service.
Icon of a medicine bottle and tablets

Painkillers

Good pain relief after your operation will boost your recovery. It will help you sleep, keep you active and reduce the chance of complications. You should not suffer pain after your operation.

You must take your painkillers regularly for the first 48 hours after surgery, even if you have no pain. If your pain is severe and not improving with the painkillers we have provided, you must contact your GP or surgical team.

Your anaesthetist will make a pain relief plan for you and your mediroom nurse or practitioner will explain it to you before you go home. Some of the medications will be provided and others you will need to purchase from a pharmacy, your local chemist or supermarket.

Paracetamol

This is a good painkiller for the type of surgery you have had.

We recommend you take 2 x 500mg tablets regularly 4 times a day for 1 or 2 days, but please check the label of the paracetamol you’ve bought and follow the instructions. If you have been given paracetamol prescribed by your anaesthetist before your operation, please remember it is perfectly safe to take 2 x 500mg tablets every 6 hours.

Remember not to take any other tablets containing paracetamol, such as co-dydramol or co-codamol. You should take these tablets even if you have no pain, as they will keep the pain away. Paracetamol works in a unique way and will work with other painkillers.

You will be advised on the time your next dose is due.

Ibuprofen

This is an anti-inflammatory painkiller.

The dose is normally 1 x 400mg tablet 3 times a day, but check the label of the preparation you have. If you can take ibuprofen, it should be taken regularly with paracetamol. Do not take ibuprofen at the same time as other anti-inflammatories such as aspirin, Nurofen, Brufen or Naproxen.

Ibuprofen has few side effects:

  • It can sometimes cause indigestion, so they should be taken with food. If you develop indigestion or abdominal pain, stop taking them.
  • If they make you wheezy or breathless stop taking them.

If you are not sure if you can have them please read the label or ask your mediroom nurse or practitioner.

Anti-inflammatory tablets can be taken at the same time as codeine phosphate and will improve your pain relief.

You will be advised on the time your next dose is due.

Codeine phosphate (30mg tablets)

Some patients will be given codeine to have on top of their paracetamol and/or ibuprofen. If you should already be taking these regularly you should continue to do so, otherwise you do not have to take codeine.

You do not have to take codeine regularly, it is a stronger painkiller which can be helpful if regular paracetamol and/or ibuprofen are not enough on their own to help with your pain.

Codeine may have side effects such as nausea, drowsiness, dizziness or constipation (taking plenty of fluids and some fruit helps avoid constipation). If, however, the side effects are unpleasant, stop taking them and consult your GP or pharmacist.

1 or 2 codeine tablets can be taken up to 4 times a day for added pain relief. Do not exceed the prescribed dose.

You will be advised on the time your next dose is due.

Anti-sickness

Acupressure has been shown to work as well as anti-sickness medications, in treating and preventing nausea. You can do this at home, by pressing on the P6 point: 3 centimetres above the wrist crease in the middle of the palm side of your arm. Watch a video on relieving nausea.

If you are at risk of feeling sick, you will be given some Ondansetron (4mg) tablets. This is an anti-sickness tablet, which can be taken up to three times per day and used alongside acupressure. Take as directed: 1 x 4mg tablets every 8 hours. If the nausea persists, please contact us or your GP.

You will be advised on the time your next dose is due.

If you are already on long term painkillers, you may need to stop taking them while you are taking these tablets. Please check with your mediroom nurse or practitioner before you leave the hospital.

 

If you or the individual you are caring for need support reading this leaflet please ask a member of staff for advice.

If you’re an overseas visitor, you may need to pay for your treatment or you could face fraud or bribery charges, so please contact the overseas office:

Taking and Sending Pregnancy Loss and Live Patient Samples for Genetic Testing

Regular Off Off

Information Sheet 2: Taking and Sending Pregnancy Loss and Live Patient Samples for Genetic Testing

Tel: 0117 414 6150
E-Mail: swglhprenatal@nbt.nhs.uk

Suitable samples:

Suitable samples for genetic testing of pregnancy loss are biopsies of skin, cord or placenta.  Samples may be refrigerated (4oC) overnight.  DO NOT freeze any samples.

NOTE: A sample of fresh placental tissue may be sent in addition to/instead of fetal tissue.

Container:

All samples should be put in a sterile container, such as a plastic universal containing tissue biopsy medium, if available, or sterile normal saline.  
Plastic universals containing skin biopsy medium are available, on request, from the laboratory.  If stored frozen (-20oC) the media has a shelf life of 3 months.  Media is likely to arrive defrosted, this is not an issue so please do not discard it.  Please re-freeze until day of use.  Please ensure tissue biopsy medium is completely defrosted prior to use and that the media is clear when held up to the light.  Non-sterile containers and those contaminated with formalin or formal saline are not suitable.  Please do not send pregnancy loss samples in CVS media, the skin biopsy media has additional reagents that will protect the pregnancy loss samples from a wider range of infections.
 

Transport:

Send by post or hospital transport to the address below, including an appropriately completed referral form which can be downloaded on the Bristol Genetics Laboratory (BGL) page.

Bristol Genetics Laboratory, Severn Pathology, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB

In the event of anticipated postal delay, (e.g. bank holidays) samples may be sent by courier, as long as arrival is within working hours.  Please inform the laboratory of the expected time of arrival. The majority of samples received by the laboratory within 3 days of being taken produce a result.

Skin biopsy from fetus/stillbirth

  • The biopsy is usually taken from the upper outer thigh within the area normally covered by the nappy
  • Rinse the limbs thoroughly with sterile normal saline
  • Using sterile instruments, cut an ellipse of skin 1-1.5cm in length (Fig. 1) to a depth which includes the full thickness of the skin and a small amount of underlying subcutaneous fat, and place in a sterile container of skin biopsy medium or sterile saline. 
  • For samples requiring fibroblast culture for storage or metabolic testing please send the sample in skin biopsy medium and as soon as possible after death to increase the likelihood of cell growth in culture

The ellipse should leave the fetus with minimal damage which can be easily repaired by clinicians or at post mortem (Fig. 2)

Fig 1 - An ellipse of skin taken at Post Mortem

 

 

 

 

 

 

 

 

Fig 1: An ellipse of skin taken at Post Mortem for genetic testing (please do not take smaller biopsies than the size shown.

Fig 2 - Site of biopsy after removal of sample

 

 

 

 

 

 

 

Fig 2: Site of biopsy after removal of sample sent for genetic testing.

Skin biopsy from live patient: 

  • The biopsy is usually taken from the inside of forearms, the upper thigh or (in babies) the iliac crest.  A local anaesthetic may be used if required.
  • Clean the skin surface with ether/alcohol and allow to dry
  • Hold the piece of skin in fine forceps, placed horizontally to skin surface so a hump of skin 5-10mm long, 1-2mm wide and 1-2mm high projects above the edge of the shafts.
  • Exert gentle pressure for 30 seconds, until the skin becomes pale and translucent.
  • Remove the protruding skin with a sterile scalpel.  Place in skin biopsy medium.
  • These samples should be sent by hospital transport or first class post as delays reduce the chance of culture success
  • Please use skin biopsy medium to increase the chance of culture success.

NOTE:  The biopsy should be deep enough to include at some point the whole thickness of the epidermis and adjacent connective tissue.

Fig 3 - A section of cord sent for genetic testing

 

 

 

 

 

 

 

 

Fig. 3: A section of cord sent for genetic testing (approximate length 2cm, diameter 1cm)

 Cord biopsy from fetus/stillbirth: 

Cord samples are a good alternative to skin and can be taken without damaging the fetus.  Cord samples can be used for routine genetic testing, although DNA quantity may be low. If possible please send a cross section of the cord (Fig. 3) of at least 2cm length (longer if the cord is from a loss at an early gestation as it is the total amount of material available that is important).  Please send following the instructions outlined in the skin biopsy section.

Placental biopsy from fetus/stillbirth:

Fresh placental tissue is suitable for DNA extraction and testing, or cell culture instead of/in addition to fetal tissue where available (Fig’s 4 & 5).  Please send a sample of chorionic villi as shown in the image below.  Please do not send:


•    large ERPCs
•    Whole fetuses unless from a very early gestation (first trimester only) as we do not have the equipment or resources to handle them

Large ERPCs or whole fetuses from a later gestation will be returned unprocessed for an appropriate sample to be obtained and sent for testing.  If the resources to take an appropriate sample are not available to the referring department, we recommend contacting a pathology laboratory at the referring Hospital for a biopsy to be taken and forwarded to BGL.
 

Fig 4 - Whole placenta with cord attached

 

 

 

 

 

 

 

 

Fig. 4: Whole placenta with cord attached. Image shows placental villous biopsy being taken from beneath the fetal surface

Fig 5 - Placental biopsy taken for genetic testing

 

 

 

 

 

 

 

 

Fig 5: Placental biopsy taken for genetic testing (please do not send smaller biopsies than the one illustrated).

Cultured cell storage and DNA extraction:

DNA extraction and storage is carried out for all samples of an appropriate size.  Cultured cell storage is carried out if specifically requested, for samples from live patients and sudden infant death samples.  Informed consent must be obtained from patient/parents for storage of DNA or cultured cells. 

Please note that the responsibility for gaining informed consent for testing and/or storage of material lies with the referring clinician. Upon receipt of samples the laboratory assumes that this consent has been obtained.

Disposal of samples

Excess skin and foetal tissue will be sent for witnessed disposal.  Placenta, cord and membrane will be sent for routine clinical disposal.

Bristol Genetics Laboratory | Owner: Helena Hennessey | Approver: Catherine Delmege
Title: Information 2 - Procedure for taking solid tissue specimens.
Active Date Of This Version: 14/10/20223 | Version 21

Badger Notes at NBT

Regular Off Off A-Z of Services
Badger Notes logo

Badger Notes is now being used at NBT!

We’ve introduced a new system that offers a better experience for our Maternity Service Users.

Both North Bristol NHS Trust (NBT) and University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) jointly started using Badger Notes from 26 September 2023. In particular, Badger Notes has replaced the yellow notes folder with an app that provides access to a digital version of your records.


How does Badger Notes work?

Badger Notes allows you to:

  • See a week-by-week timeline of your pregnancy.
  • Access reading recommended by your Midwife.
  • View your hospital’s full library of maternity leaflets.
  • View booked appointments and information direct from your medical record.

Additionally, as you build a personalised care plan with your Midwife, Badger Notes gives you a place to record thoughts and questions about your antenatal care, birth plan, and postnatal care for your Midwife to review with you.

For care purposes, and once they've been granted access to Badger Notes by you, healthcare professionals such as GPs will also have 24-hour access to information.

The 2-minute video below offers a quick and simple introduction to Badger Notes at NBT and UHBW.

 

Why are we introducing Badger Notes?

Besides improved access to information, we’re doing this to deliver a better - and safer - care experience. Badger Notes is already in use at other NHS Trusts around the country including here in the South West.


How can I find out more?

Besides the video above, we’ve listed some Badger Notes questions and answers below to help.

Don't forget that your Midwife should also be able to answer any questions you may have. To find out how to get in touch, please refer to our Maternity Services contacts page.

Smartphone showing Badger Notes App

How can I access Badger Notes?

With the following options, please be aware that you can’t access your notes until you receive a ‘security phrase’ from your Midwife.

a. Using a mobile phone

iPhone - Please search for the Badger Notes app in iTunes and download. Once done, tap the icon on your home screen to open.

Android - please search for the Badger Notes app in the Google Play store and download. Once done, tap the icon on your home screen to open.


b. Using a PC or tablet
You can log in to the Badger Notes website by clicking this link: badgernotes.net

For more information, please see Badger Notes help.

If you're registered with a GP in England, you can also create an account using NHS login.

The video below shows you how to log in, and explains the various Badger Notes features.

How secure is Badger Notes?

All information is held securely and cannot be accessed without the correct login details (similar to when you use internet banking).

Can anyone else I request (family, friend, partner, doula) access my information on the app?

No – the only person who can access your information is you. For care purposes, healthcare professionals such as GPs will also have 24-hour access to information - but only once they've been granted access to Badger Notes by you.

What languages is Badger Notes available in?

It is configured to the 11 most common languages as held on/used by the Badger Notes app, as follows: English, Welsh, Polish, Punjabi, Bengali, Spanish, Portuguese, Romanian, Lithuanian, Somali, and Maori. There is also a translate function on the desktop version.

What happens if I don’t have a smartphone?

You can access Badger Notes on a home device (e.g. desktop or laptop computer, tablet) via the internet. If you do not have internet access, please speak to your Midwife.

What happens if I move Trust and my new provider doesn’t use Badger Notes?

If this is the case, a copy of your notes will be sent on to the new hospital.

 

Having a problem with logging into Badger Notes?

Have you tried these things?

  • If you registered using your NHS login details you must use the blue NHS login button to access your account: Image removed.
  • If your current details do not match your NHS login details you will need to change them via the NHS app
  • It may be helpful to try to log into the website via a web browser and not the app.
  • If your password is not recognised click on the ‘forgotten password’ button to reset it. 
  • Further help can be found at Badger Notes - Help & FAQ

 

If you are still having problems, then please call our dedicated Badger Notes helpline on 0117 3429301 or email badgernotessupport@uhbw.nhs.uk. You will be asked to quote your NHS number so please ensure you have this to hand. This is a non-urgent telephone line and is monitored 10-4 Monday to Friday and 11-3 at weekends by administrative staff. If you need to speak to a midwife, you should call your local hospital as normal.  

Pregnancy

Clinical Research Strategy 2022/27

Regular Off Off

North Bristol NHS Trust (NBT) is proud to provide hospital and community healthcare that supports our local populations across Bristol, North Somerset and South Gloucester and those we serve as part of our regional and national specialised services.

"Research forms an integral part of the Trust’s strategic aims and the delivery of the Trust’s ambitions. Encouraging a research-positive culture in healthcare is important to give patients wider access to clinical research, improving treatment outcomes, patient care and experience." Maria Kane, Chief Executive

 

Our VISION

To improve peoples’ health and care through the development and delivery of world-class research.

Our MISSION

To improve the health and wellbeing of our patients and local populations through excellence developed and delivered by a highly skilled, committed workforce; while conscious of inclusivity and minimising environmental impact.

Our STRATEGY REPORT

Research Strategy 22-27

Founding Principles

The last five years has seen substantial changes in societal attitudes and responsibilities in two significant spheres. COVID-19 and the Black Lives Matter movement have both highlighted the lack of progress healthcare and research has made in ensuring inclusivity and representation from all our communities and the consequential health and wellbeing inequalities. During the same period the NHS and NBT have declared a climate emergency in recognition of the impact on health and wellbeing that environmental factors are causing. As a result two overarching principles have been included in the new strategy.

Principle One: In everything we do we will seek true equality and inclusivity.

Principle Two: In everything we do we will seek to minimise the negative environmental impact of our actions.

 

Our Aims

Aim 1: Engage and empower patients and public as partners in our world-class research

What we will do: 

  • Enable more people to engage in public and patient involvement (PPI) and co-production of research
  • Provide research opportunities that reflect our patients’ experiences
  • Improve patient safety and experience by demonstrating and implementing research results

How we will do it:

  • We will seek to understand the logistical, cultural and language barriers which inhibit equitable and inclusive PPI with all the communities we serve. This knowledge will allow us to develop guidance to support, engage and empower underserved communities. Disseminating our learning with our healthcare partners will support best practice that is implemented system-wide.
  • We will maximise opportunities in research, that reflect the needs of our patients and communities, by raising awareness and demystifying research through the effective use of different media platforms. Research campaigns and engagement events will maximise the use of environmentally sensitive approaches. Through cross-organisational collaborations we will ensure opportunities to participate in research across the region.
  • We will work with our research and PPI partners to ensure research outcomes are disseminated to study participants in appropriate and timely ways. We will work with our colleagues across NBT and the region to implement the outcomes of research to improve health outcomes, whilst avoiding and reducing the environmental costs of repeating unnecessary research studies.
  • We will actively use our experience from previous studies to improve the design, deliverability, and efficiency of studies to ensure effective implementation, whilst reducing the negative environmental cost of research and healthcare.

What success will look like

  • The demographic profile of staff, patients and public involved in research will better reflect our local community.
  • The results of our research will be implemented into clinical care efficiently and within pre-defined timelines.

Aim 2: Support our workforce to develop and enhance their knowledge and skills to deliver world-class research

What we will do:

  • Build upon the skills of our workforce and volunteers
  • Develop the future workforce
  • Develop improved career pathways for all our research staff

How we will do it:

  • We will promote research as a dynamic career option, co-designing a suite of training programmes, supporting new starters, optimising delivery expertise, developing new and more effective ways of working and supporting courageous and compassionate leadership through training which is both inclusive and environmentally sensitive.
  • We will develop comprehensive career pathways to empower and support emerging talent to help individuals to pursue and access funding, mentorship, and coaching (academic or NHS) to realise their career and research ambitions.
  • We will promote opportunities to develop as leaders and lead researchers investing in the researchers of the future to address current issues with innovative solutions and strategies.
  • We will seek opportunities to enhance our quality improvement cycles and embed the lessons learned which includes adapting study design and delivery, providing state-of-the art research facilities and using technology proactively.

What success will look like

  • Improve our current internationally recognised “Investors in People” accreditation.
  • An increased number of non-medical researchers acting as lead researchers.

Aim 3: Ensure research is a core principle underpinning the day-to-day business of the Trust

What we will do:

  • Increase awareness of research and its impact on clinical care
  • Deliver research that improves healthcare and patient experience
  • Embed research in the care pathway of all NBT services

How we will do it:

  • We will promote the rights of patients to engage in research, and for staff to understand their opportunities and responsibilities to offer and support appropriate research, irrespective of profession, background, or characteristics. We will ensure patients and staff are supported to engage with research and the research information is easily accessible. All internal funding opportunities will be widely available, and access will be equitable, inclusive, and promoted through multiple media channels
  • We will actively engage with clinical divisions and healthcare education programmes to demystify research and promote research as everyone’s right and responsibility. This will enable current and future clinicians to address clinical questions that improve the health and experience of our patients and communities.
  • We will work with clinical and leadership teams to focus and embed research within clinical pathways and staff job plans, ensuring results are disseminated through departments and divisions in a timely manner. We will ensure the time our staff invest in our research is recognised and appreciated, helping to raise awareness of the value and contribution research makes in clinical practice.
  • We will co-design an adoption process with the Trust Transformation team to facilitate the implementation of research findings at NBT, agreeing targets for implementing research findings and demonstrate the value of evidence-informed and value-based practice across all clinical areas.

What will success look like?

  • An increase in research awareness and engagement amongst patients and staff.
  • An increase in the number of research findings being implemented at NBT.

Aim 4: Further develop our expertise in research design, management, and delivery to make NBT a national exemplar for cross-system research and innovation

What we will do:

  • Build on our reputation for cross-system research and innovation to make us the collaborator and centre of choice
  • Identify our strengths, clinical priorities, and opportunities to develop and deliver world-leading research
  • Ensure efficient resource utilisation for the delivery of NBT and cross-system research

How we will do it:

  • We will develop and maintain with our regional partners, a suite of best practice guidance, policies, and agreements to enhance efficient and seamless processes. These will maximise research productivity and income in regionally strategic areas which will also promote inclusivity and be environmentally sensitive.
  • We will continue to explore and deploy new research methodologies suitable to pragmatic health and social care research, including working with NBT Information Governance, and Digital Services and Technology to implement and deliver big data projects efficiently and effectively. New approaches will allow us to broaden and diversify our research portfolio focusing on under-represented professions, specialities, and communities.
  • We will embed quality improvement in everyday practice to enhance the design and delivery of the research led and delivered by NBT. We will work with regional partners to develop and share best practice, facilities, training, and infrastructure. This will, in turn, improve our efficiency in the way we deliver research thus enabling further investment in our teams and facilities.

What will success look like?

  • A comprehensive suite of guidance which supports cross regional research.
  • We will lead and implement adaptive pragmatic solutions to delivery challenges.

Review of our Research 2017-2022

Research at North Bristol NHS Trust (2017-2022)

Helen Lewis-White, Deputy Director Research & Development

We are delighted at how much we have achieved as a research community over the last five years. NBT has offered increasing opportunities for our communities to become involved in research, doubling recruitment into clinical research between 2017-2022.

NBT’s grant success over the last 5 years has been firmly based on high quality Patient & Public Involvement (PPI), ensuring we are seeking the answers to questions most relevant to our patients and the clinical services we deliver. During that time nearly 250 PPI meetings supporting 20+ research groups have worked together to define and refine research ideas, approaches and interventions, and to monitor the progress of studies as members of trial management groups.

During the same five year period, the number of departments offering research grew from 45 to 55 resulting in research taking place across every division of the Trust. In addition 8000 participants were directly recruited at North Bristol NHS Trust. We currently lead over 30 multi-centre studies across 100 Trusts throughout England and the devolved nations, offering new opportunities for patients and participants to engage in research.

The primary role of everyone within the Trust’s research infrastructure is to enable patients and the public to engage in relevant research opportunities, helping to shape healthcare for the future. For some, research may offer a new or additional treatment option, but for many people who participate in research the benefit for them is knowing they are contributing to improving care and outcomes for others.

“It’s clear that the medical community are continually trying to answer new questions, but they can only do this with the help of patients. As a lay member of the public, we don’t understand fancy medical vocabulary, so we have to dream up new ways of describing medical terms. We also have to think of ways to make our research programme interesting and to encourage as many people as possible to sign up.” Public & Patient Involvement Member.

“I know my Alzheimer’s is not going to get better. I decided to take part in research because it might just help people with this disease in the future” Research Participant

The NBT Research & Development team supports all aspects of research activities supporting the different developmental stages of research. From exploration of ideas, through qualitative ‘question finding’, through to the dissemination and implementation of findings from these clinical trials into real world practice for population health benefit.

Research at NBT is a multi-disciplinary and multi-specialist activity incorporating patient and members of the public, whose specialist lived experience provides our teams with essential and unique perspectives. This allows the research teams to work closely with Patient and Public Involvement (PPI) representatives, to co-develop and shape the important research questions, design the most appropriate study format, and to then monitor the progress of studies through to completion. Finally, the teams will then support the wider public dissemination of study findings and appropriate implementation, leading to an improvement in, or a change to, the delivery of clinical services.

NBT currently manages £28 million in research grants with an annual grant income of approximately £2.5 million. During the last five years the breadth and scope of the grants supported and awarded has grown significantly and we are currently leading 60 research grants and partnering on a further 59 externally led grants.

To enable the increase in patient opportunities to participate across the research landscape the NBT research infrastructure has grown from 115 staff members to over 140 individuals. We have also continued our commitment to invest in and develop our team members. In 2019 R&I was awarded an Investors in People Silver accreditation in recognition of the programme of work the R&I infrastructure has undertaken supporting, and improving how we work as individuals, teams and as a department, and developing our leaders now and for the future.

Collaborations with North Bristol NHS Trust

NBT prides itself on the strength of its research collaborations across a wide range of academic affiliations, healthcare settings, and industry partners.

Academic Health Science Centre (AHSC) which focuses on close collaborative system-working across the Bristol, North Somerset, and South Gloucestershire (BNSSG) Integrated Care System (ICS). The partnership enables the best use of the regional academic research infrastructure, combined with the implementation and evaluation expertise and activities led by the West of England Academic Health Science Network, directly informing the work of the BNSSG ICS.

We now aspire to build upon the previous NBT research strategies and our experiences throughout the COVID-19 pandemic, which has driven and shaped how research is now conceived, developed, and delivered.

Our academic links with globally recognised academic research institutions including the University of Bristol, University of Bath, and University of the West of England (UWE) have contributed significantly to our success. Through these collaborations NBT ensures the research we lead is patient centred, clinically important, and pragmatically delivered.

Throughout the last five years, and particularly the last two years during the COVID-19 pandemic, our collaborations have driven our continued strength and growth. Through these collaborations and mutual support NBT helped lead the regional COVID-19 vaccine research response, supporting other Trusts to recruit to COVID-19 pandemic vaccine trials across the West of England region. NBT continues to support and lead the NIHR Comprehensive Research Network: West of England (CRN:WE) and to work with partner Trusts across the region to develop novel quality improvement programmes, innovation in research delivery, and to share best practice.

NBT also benefits from being a leading and founder member of the vibrant and ambitious strategic health research and innovation partnership, Bristol Health Partners

“Generating a research culture requires innovation, creativity, engagement and skill. Here at NBT we are instilling a collaborative research culture across all areas of the Trust to ensure research stays at the heart of what we do.”

Dr Tim Whittlestone, Chief Medical Officer

2017-2022 Highlighted Achievements

Below are a few examples of the research achievements at NBT from across the lifespan of our patient population, realised through close collaborative working with our patients and partners.

STAR Programme

The STAR Programme developed and tested a care pathway for the one in five patients who will experience chronic pain three months after knee replacement surgery. STAR identified underlying causes of chronic pain and enabled onward referral for targeted treatment through screening, assessment with an extended scope practitioner, and telephone follow-up over 12 months. STAR demonstrated clinically important improvements in pain and recovery, and is good value for money, reducing hospital admissions and length of stay.

The STAR care pathway was implemented at NBT within six months of the final report to the NIHR, and is now being rolled out nationally, with the potential to improve pain and recovery for over 20,000 patients each year alongside annual NHS cost savings of over £14 million.

ASSIST

The ASSIST trial has tested a new device for assisted vaginal births and is the first potential device for assisted birth since the introduction of the ventouse suction cup, in the 1960s. For this trial a major success has been the use of alternative patient information methods. The study team developed videos to explain the study, demonstrating how the device works on a mannequin doll and including answers to common questions. Women and partners were able to watch the video at their leisure and given another opportunity to ask questions. The use of a freely accessible video combined with both a brief and detailed patient information leaflet was commended by the Research Ethics Committee (REC) for facilitating parents understanding of the study during emotive and challenging times.

CERA: COVID-19 Emergency Response Assessment

In collaboration with the University of Bath the CERA study explored the emotional impact of the COVID-19 pandemic on frontline Emergency Room and Intensive Care Unit medics. It demonstrated the significant psychological toll the COVID-19 pandemic was exerting and helped highlight the need for greater focus on mental health and wellbeing. It was particularly useful in highlighting the challenges medics feel in seeking assistance, and the fear and shame they experience when they admitted their emotional wellbeing is being affected by their role.

AERATOR

Aerator, a collaboration with the University of Bristol, tested the aerolisation of procedures during COVID-19 pandemic in multiple clinical settings. The study design enabled rapid assessment and dissemination. The results of the Aerator study were used extensively to inform the levels of personal protective equipment policy nationally and internationally. This both protected staff and patients but also enabled an evidence base for reducing unnecessary infection control procedures and enabling clinics to increase their capacity and begin to address patient backlogs.

Aerator also made use of innovative mechanisms for engaging clinicians and the public with the results of the study, using a comic strip to explain the issue and the results, ensuring the results were more accessible. https://artibiotics.com/blog/aerator

Looking Forward

Developing the new NBT research strategy (2022-2027)

This new research strategy outlines our ambitions for the next five years. It complements and supports the Trust’s values and underpins the behaviour and principles of every member of staff.

Our strategy will describe what we plan to achieve, the objectives we will need to meet them, and the additional steps we will be undertaking to further embed research within patient pathways and our community. At the same time, it is essential we remain agile to changing priorities as they arise, through constant monitoring of our research portfolio and how it informs and is shaped by health and care delivery across the BNSSG ICS.

While this strategy is specific to clinical research, we recognise a culture of innovation is a key element of ensuring research is converted to clinical change and patient benefit which forms the bedrock of the research cycle.

With empowerment as a core principle of our strategy, we aim to:

  • Empower patients and public as co-producers of research
  • Empower clinical staff to address questions they believe will improve patient care
  • Empower researchers with the skills and knowledge to best deliver the research they undertake and lead on
  • Ensure patients and the public are key contributors and collaborators within our research environment
  • Empower all our communities to hold us to account and create equity of access and inclusivity whilst ensuring our research is environmentally responsible.

Since 2016 each review of the strategy has been shaped through stakeholders’ consultation exercises, questionnaires, meetings, and conferences. These include the researchers who generate our research, the teams who deliver the strategy and our regional strategic partners and stakeholders. Each year we monitor our progress and report to the Trust Board. In 2020 our primary focus shifted to helping answer critical questions about the spread, prevention, and treatment of COVID-19, noting that the epidemic disrupted many of our other research activities resulting in some objectives not being completed, whilst other key activities became more urgent.

Whilst the Trust and R&I department has achieved so much against the delivery plans for the 2017-2022 strategy, changes to health and social care priorities, technologies and wider social change means the Trust now requires a new strategy to take it through the next five years. To develop the new strategy, we consulted widely with internal and external stakeholders undertaking the following engagement activities:

  • A survey distributed across the research teams, research active clinical staff, managers and all NBT Trust email address recipients to ask whether the Vision, Mission and Aims represented the aspirations and commitments of our teams, partners, and stakeholders.
  • A series of meetings were held in early 2022 to better understand the objectives, aspirations, and ambitions which we should endeavour to pursue through our strategy.
  • The comments and feedback were collated and contributed to the formulation of the Vision, Mission, Aims and Objectives, which were then disseminated for further and wider consultation with internal and external stakeholders.

The last five years has seen substantial changes in societal attitudes and responsibilities in two significant spheres. COVID-19 and the Black Lives Matter movement have both highlighted the lack of progress healthcare and research has made in ensuring inclusivity and representation from all our communities, and the consequential health and wellbeing inequalities. During the same period the NHS and NBT have declared a climate emergency in recognition of the impact on health and wellbeing that environmental factors are causing.

Founding Principles

Following the above consultation and engagement activities, two overarching principles have been included in the new strategy as we seek to embed these attitudes and behaviours in the research developed, supported, and delivered at NBT:

Principle One

In everything we do we will seek true equality and inclusivity.

Principle Two

In everything we do we will seek to minimise the negative environmental impact of our actions.

Stakeholders we engaged with

Internal Stakeholders

  • The research infrastructure
  • Research Leads
  • Research Innovation Group
  • Divisional Clinical Directors
  • Divisional Directors
  • The Trust Equality and Inclusivity forums
  • NBT PPI groups
  • Southmead Hospital Charity
  • The Staff of NBT

External Stakeholders

  • University Hospitals Bristol and Weston NHS
  • Foundation Trust
  • Avon and Wiltshire Mental Health Partnership
  • NHS Trust
  • University of Bristol
  • University of Bath
  • University of the West of England
  • NIHR Bristol Biomedical Research Centre
  • NIHR West of England Clinical Research Network
  • NIHR Applied Research Collaboration West
  • Bristol Health Partners Academic Health Science Centre
  • West of England Academic Health Science Network
  • Healthier Together BNSSG Integrated Care System

A PDF version of this Strategy Report is available

Please email researchcommunications@nbt.nhs.uk

Our Research

Regular Off Off

North Bristol NHS Trust is committed to research that can improve the outcome of its patients and their experience of its services.

Working collaboratively with care providers across the geographical area, we seek to ensure that everyone we meet has equal access to research. With patients and the public at the heart of all we do, our four main aims are; to empower patients in research, support and nurture our workforce, make research visible in day to day activity, and work with our regional partners to improve healthcare.

This commitment has enabled us to deliver research both on time and to target, which ultimately leads to the highest quality outcomes and improved care for our patients.

Every year 12,000 participants take part in research at our Trust. Watch a video with few of their stories, alongside those of dedicated research staff.

Why we do research video screenshot

 

Take Part in Research

Patient & Doctor viewing an x-ray

Become one of the thousands of people taking part in research every day within the NHS.

Meet the Research & Development Team

Research Nurses at NBT

Want to find out more about our research? Simply get in touch with a member of our team here.

Contact Research

Research & Development
North Bristol NHS Trust
Level 3, Learning & Research building
Southmead Hospital
Westbury-on-Trym
Bristol, BS10 5NB

Telephone: 0117 4149330
Email: research@nbt.nhs.uk

R&I Our Research Banner.png